Hualin Chen1, Yiping Luo1, Muwen Lin1, Xiaoxia Peng1, Meilian Liu1, Zhong Huang1, Yongcun Wang1, Shujun Li1, Donghong Yang2,*, Zhixiong Yang1,*
1Department of Pulmonary Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, Guangdong, China - 2Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524023, Guangdong, China
Introduction: We aimed to explore the efficacy and safety of Anlotinib combined with icotinib in the treatment of advanced non-small-cell lung cancer (NSCLC).
Materials and methods: 23 patients with local advanced/advanced NSCLC with epidermal growth factor receptor (EGFR)-positive were included in this study. All patients received oral icotinib and anlotinib.
Results: The disease control rate of the whole population was 78%. The progression-free survival (PFS) rate at the 20th month was 70.58%. Moreover, the average medication cycle of the whole population was (13.2 ± 7.8), and the median medication cycle was 10(1-38). The most common adverse reactions were hypertension (47.83%) and hand-foot syndrome (43.48%). There were three cases of grade 3 adverse reactions, including hand-foot syndrome, hypertension, and diarrhea.
Conclusion: For patients with local advanced/advanced NSCLC with EGFR-positive, Anlotinib combined with icotinib can not only delay the drug resistance to achieve better clinical efficacy, but also has good safety and tolerability.
advanced non-small cell lung cancer, safety, Anlotinib, icotinib, efficacy.
10.19193/0393-6384_2022_3_311